Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease
Parkinson's Disease
About this trial
This is an interventional treatment trial for Parkinson's Disease focused on measuring Parkinson's disease, Coenzyme Q10, Treatment, Neuroprotection
Eligibility Criteria
Inclusion Criteria: Parkinson's disease according to the UK Brain Bank criteria Hoehn & Yahr stadium II until III Male or female Age 40 to 75 years UPDRS Part III > 15 points No motor fluctuations or dyskinesias Stable parkinsonian condition for 4 weeks prior to inclusion Outpatients Patients without or with stable levodopa treatment for 4 weeks prior inclusion Written informed consent Exclusion Criteria: Atypical or drug-induced parkinsonian syndromes Dyskinesias or motor fluctuations Coenzyme Q10 treatment in the past Pregnancy Epileptic seizures in the history Hypothyroidism Severe medical conditions with interference with study drug Treatment with CSE inhibitors, thyroidal hormones, antiarrhythmic drugs, warfarin, metformin Treatment or intake of vitamins, magnesium, vitamin E, calcium
Sites / Locations
- Department of Neurology, University of Ulm
- Department of Neurology, Fachklinik Ichenhausen
- Department of Neurology, Leopoldina Krankenhaus
- Department of Neurology, University of Marburg
- Department of Neurology, Deutsche Klinik fuer Diagnostik
- Department of Nuerology, Klinikum Lippe
- Department of Neurology, Klinikum Lueneburg
- Department of Neurology, Ruhr-University of Bochum
- Department of Neurology, Klinikum Essen-Borbeck
- Department of Neurology, Klinik Ambrock
- Department of Neurology, University of Homburg
- Department of Neurology, Technical University of Dresden
- Department of Neurology, Charite Berlin